Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences GlobeNewswire November 05, 2025 GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings […]

Jayud Global Logistics Selected by Lenovo Group for Warehousing, Logistics, and Supply Chain Management Services

Jayud Global Logistics Selected by Lenovo Group for Warehousing, Logistics, and Supply Chain Management Services GlobeNewswire November 05, 2025 SHENZHEN, China, Nov. 05, 2025 (GLOBE NEWSWIRE) — Jayud Global Logistics Limited (NASDAQ: JYD) (“Jayud” or the “Company”), a leading end-to-end supply chain solution provider based in Shenzhen, specializing in cross-border logistics, today announced that it

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Host Virtual Investor Event on Ersodetug Development Program Webcast scheduled for Monday, November 10 at 12:00 pm EST GlobeNewswire November 05, 2025 REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced

MediWound to Report Third Quarter 2025 Financial Results

MediWound to Report Third Quarter 2025 Financial Results GlobeNewswire November 05, 2025 MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 05, 2025 Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival

Habit Burger & Grill Celebrates Launch of Reedley Drive-Thru Restaurant

Habit Burger & Grill Celebrates Launch of Reedley Drive-Thru Restaurant GlobeNewswire November 05, 2025 New California Habit Restaurant to Open Doors on November 12Hold Pre-Opening VIP Event on November 8 IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Habit Burger & Grill, the California-based restaurant company renowned for its award-winning Charburgers grilled over an open

Crescent Biopharma to Present at November Investor Conferences

Crescent Biopharma to Present at November Investor Conferences GlobeNewswire November 05, 2025 WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following

TERRA CLEAN CLOSES $2.5 MILLION LIFE OFFERING

TERRA CLEAN CLOSES $2.5 MILLION LIFE OFFERING GlobeNewswire November 05, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver B.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company“) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0) is pleased to announce, that further

AI takes the lead: Flexera report reveals priorities driving IT strategy for 2026

AI takes the lead: Flexera report reveals priorities driving IT strategy for 2026 One in three IT leaders stated AI integration as their top priority for next year in the Flexera 2026 IT Priorities Report GlobeNewswire November 05, 2025 ITASCA, Ill., Nov. 05, 2025 (GLOBE NEWSWIRE) — Flexera, the global leader in technology spend and

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

(NasdaqGM:VERA), ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in

Scroll to Top